| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Intensity Therapeutics, Inc.$4.78
-0.13 (-2.65%)
D 36Pipeline Score Fair Value Biotech · Clinical
Market Cap
12.73 M
EPS
-7.08
P/E Ratio
-
Value Trade
156.44 K
SEC Financials
Q1 2026Dilution Risk
25%R&D Expenses
1.20 M
Operating CF
-1.83 M
Total Assets
12.29 M
Total Liabilities
2.31 M
Equity
9.98 M
D/E Ratio
12,345
-2.08 %
Week
-10.96 %
1 Month
-23.54 %
3 Month
-50.09 %
6 Month
-96.83 %
5 Year
-96.83 %
All Time
Cash Data
Cash Position
10.24 M
Monthly Burn
609.00 K
Runway
14.9 mo
Burn Trend
SEC Filing
May 7, 2026
Overview
Volume
29.25 K
52 Week Range
4.50 - 43.50
% held by Insiders
4.73 %
% held by Institutions
6.08 %
Enterprise Value
2.59 M
Total Shares
2.54 M
Short %
5.29 %
Float Shares
2.39 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Intensity Therapeutics, Inc.
152Total events
4Upcoming
13Tier-1 (high impact)
2023 – 2027Coverage
Upcoming catalysts 4
2026-H2
T2Publication
Plan to report clinical data from two completed studies in additional peer-reviewed publications in H2 2026
Event history 148
Q3 2026
◆Enrollment UpdateINT230-6Trial
Plan to resume enrollment in INVINCIBLE-4 in Switzerland and France in Q3 2026
presurgical triple-negative breast cancersource ↗
Jul 1, 2026
▲PublicationINT230-6Presentation
Peer-reviewed publication in eBioMedicine (Lancet Discovery Science) reporting clinical observations
advanced solid tumorssource ↗
Jun 2026
▲Partnership / LicenseINT230-6Corporate
Active strategic partnering initiatives; over 20 partnering discussions at BIO 2026
Apr 2026
▲Enrollment UpdateINT230-6Trial
Resumption of enrollment in INVINCIBLE-3 study announced in April 2026
soft tissue sarcomasource ↗
Q2 2026
◆Trial InitiationINT230-6Trial
Expect to initiate enrollment in France in Q2 or Q3 2026
triple negative breast cancersource ↗
Mar 31, 2026
Mar 26, 2026
▲IND ClearanceINT230-6IND
Full approval to resume enrollment in INVINCIBLE-4 granted by Swissmedic and Swiss Ethics Committee
presurgical triple-negative breast cancersource ↗
Mar 26, 2026
▲Enrollment PausedINT230-6Trial
Enrollment paused; approval to resume granted March 26, 2026
triple negative breast cancersource ↗
Mar 6, 2026
Mar 2, 2026
▲Safety Data UpdateINT230-6Clinical Data
Safety data through March 2, 2026 shows favorable safety for INT230-6 plus SOC vs SOC alone
triple-negative breast cancersource ↗
Mar 2026
●Protocol AmendmentINT230-6Trial
Protocol amendment submitted to Swissmedic and Swiss Ethics Committee for INVINCIBLE-4 study
presurgical triple-negative breast cancersource ↗
Drug Pipeline Intelligence
D36
Pipeline Score $26M
Pipeline ValueFair Value
Valuation Signal1
Drugs Scored2.0x
rNPV / MCap Top 50%
Micro Cap (rank 456 of 911)
Percentile RankIntensity Therapeutics, Inc. faces pipeline headwinds (36/100), with $1.2B risk-adjusted pipeline value, led by INT230-6 in Sarcoma,Soft Tissue (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| INT230-6 Small molecule | Sarcoma,Soft Tissue | Phase 3 | NCT06263231 | 56% | $1.2B | ACTIVE NOT_RECRUITING | 333 | AVERAGE | C (51) | Dec 1, 2028 | MODERATE_RISK | LOW May 26, 2026 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
INT230-6 Orphan | triple-negative breast cancer | Phase 2 | 2026-03-12 | adverse events: 44% reduction in grade 3 or higher adverse events Read More | Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Read More | |
INT230-6 Orphan | triple-negative breast cancer | Phase 2 | 2026-03-12 | adverse events: 44% reduction in grade 3 or higher adverse events Read More | Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Read More | |
INT230-6 Orphan | triple-negative breast cancer | Phase 2 | 2026-03-12 | adverse events: 44% reduction in grade 3 or higher adverse events Read More | Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in INTS
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
INTS Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
INTSIntensity Therapeutics Provides Mid-Year Update Highlighting Late-Stage Development Programs and Strategic Partnering Opportunities for INT230-6
Intensity Therapeutics provided a mid-year update on its late-stage development programs, particularly focusing on INT230-6 for soft tissue sarcoma and presurgical triple-negative breast cancer. The company reported positive preliminary outcomes from clinical studies and is actively pursuing strategic partnerships to enhance development. Despite some funding constraints affecting enrollment, Intensity's financial position remains strong.
Read more →INTSIntensity Therapeutics Recognized with GHP Magazine's 2026 Healthcare & Pharmaceutical Award
Intensity Therapeutics has been recognized as the Cancer Treatment Technology Innovator of the Year 2026 by GHP Magazine. This award highlights the company's innovative approach to cancer therapies, particularly its lead product INT230-6, which has shown encouraging results in clinical trials for patients with advanced cancers. The recognition underscores Intensity's commitment to improving cancer care and patient outcomes.
Read more →INTSIntensity Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update Cash and cash equivalents of $10.2 million as of
Intensity Therapeutics has reported favorable preliminary results from its INVINCIBLE-4 Study in early-stage triple negative breast cancer patients, indicating improved efficacy with its drug INT230-6. The company plans to resume enrolling patients in both INVINCIBLE-4 and INVINCIBLE-3 Studies by mid-2026, contingent upon securing additional funding. Financially, Intensity reported a lower net loss in the first quarter of 2026 compared to the same period last year, alongside cash reserves of $10.2 million. The ongoing focus remains on developing effective cancer therapies addressing high unmet needs.
Read more →INTSIntensity Therapeutics Recognized with Pinnacle Award for Excellence in Healthcare Innovation
Intensity Therapeutics has been awarded the Platinum Award for Innovator in Biotech Solutions at the 2026 Pinnacle Awards for its lead drug candidate INT230-6. This investigational product is designed for direct intratumoral injection and combines two potent anti-cancer agents. The award underscores the company's innovative approach to cancer treatment and its potential to change the treatment landscape.
Read more →INTS▼ -5.8%on this news
Intensity Therapeutics Reports 2025 Year End Financial Results and Highlights, and Provides Corporate Update
Intensity Therapeutics provided a corporate update alongside its 2025 financial results, highlighting the ongoing INVINCIBLE-4 and INVINCIBLE-3 studies. The company has raised over $20 million to extend its cash runway and plans to resume patient enrollment in its trials. Despite a net loss of $11.6 million, the company remains optimistic about its novel cancer therapy, INT230-6.
Read more →INTSIntensity Therapeutics Strengthens IP Portfolio with Issuance of New Patent in the US
Intensity Therapeutics announced the issuance of a new US patent, enhancing its intellectual property portfolio. The patent, US Patent Number 12,496,345, is part of the company's efforts to protect its innovative cancer therapies. With four US patents and coverage in 41 countries, Intensity aims to advance its lead product candidate, INT230-6, in ongoing clinical trials.
Read more →INTS▼ -6.2%on this news· ran to -18% by day 3
Intensity Therapeutics, Inc. Provides Update on the Phase 2 Presurgical Triple-Negative Breast Cancer INVINCIBLE-4 Study
Intensity Therapeutics has provided an update on its Phase 2 INVINCIBLE-4 study for presurgical triple-negative breast cancer. The study's enrollment was paused due to skin irritations, but a protocol amendment has been submitted to resume using a lower drug volume. Preliminary data shows promising pCR rates and favorable safety profiles compared to standard treatments. The company plans to present more detailed results at an upcoming oncology conference.
Read more →INTSIntensity Therapeutics Regains Compliance with Nasdaq's Minimum Bid Price Requirement Shelton, Conn.
Intensity Therapeutics, Inc. has announced that it has regained compliance with Nasdaq's listing requirements after its stock maintained a bid price above $1.00 for ten consecutive business days. This announcement indicates strong market performance and supports the company’s ongoing development of its lead product, INT230-6, which is undergoing several clinical trials for various cancers. The therapy represents a novel approach to cancer treatment, aiming to improve both local control and systemic immune response.
Read more →INTSUpdated as of
Updated as of
Read more →INTS▼ -32.6%on this news
Intensity Therapeutics Announces Reverse Stock Split
Intensity Therapeutics has announced a 1-for-25 reverse stock split, effective February 18, 2026, to comply with Nasdaq's minimum bid price requirement. This action will reduce the number of outstanding shares significantly while maintaining the total authorized shares. The company continues to advance its investigational product INT230-6, which targets cancer treatment through direct intratumoral injection.
Read more →INTSIntensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities
Intensity Therapeutics has outlined its strategic priorities for 2026, highlighting key achievements from 2025. The company emphasizes its clinically validated product INT230-6, which is designed for direct tumor injection and shows promise in cancer treatment. With a strengthened balance sheet, Intensity aims to advance its clinical programs and regulatory engagements while focusing on generating high-quality clinical data.
Read more →INTS▲ +7.3%on this news· ran to -20% by day 3
Intensity Therapeutics, Inc. to Present Two Posters at the 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics, Inc. will present two posters at the 2025 San Antonio Breast Cancer Symposium, showcasing early observations from the INVINCIBLE-4 study on INT230-6 for treating Triple Negative Breast Cancer (TNBC). The presentations highlight potential modifications to treatment protocols and the promise of a safer alternative to traditional therapies. The company aims to advance to a Phase 3 trial based on favorable safety and efficacy results.
Read more →INTS▲ +10.8%on this news
Intensity Therapeutics Granted 180-Day Extension to Regain Compliance with Nasdaq's Minimum Bid Price Requirement
Intensity Therapeutics has been granted a 180-day extension by Nasdaq to meet the minimum bid price requirement. The company must maintain a closing bid price of at least $1.00 for ten consecutive business days by June 1, 2026. This extension follows an initial compliance period that expired on December 3, 2025. The company is actively monitoring its stock price to regain compliance.
Read more →INTS▲ +12.3%on this news· ran to +29% by day 3shared move
Intensity Therapeutics Announces Two Presentations at the Upcoming 2025 San Antonio Breast Cancer Symposium
Intensity Therapeutics has announced two presentations at the 2025 San Antonio Breast Cancer Symposium, showcasing their lead product candidate INT230-6. This investigational drug is designed for direct intratumoral injection and combines two potent anti-cancer agents with a unique enhancer. The company aims to demonstrate its potential to improve cancer treatment outcomes and engage the immune system effectively.
Read more →INTS▼ -6.2%on this news
Intensity Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Intensity Therapeutics reported its third quarter 2025 financial results, highlighting a successful fundraising effort that extended its cash runway until early 2027. The company plans to resume patient enrollment in its INVINCIBLE-4 study after revising the dosing regimen due to localized skin irritation in some patients. Additionally, a peer-reviewed publication on INT230-6 supports its efficacy in treating advanced solid tumors.
Read more →INTS▼ -44.7%on this news· ran to -57% by day 3
Intensity Therapeutics, Inc. Announces Pricing of $4 Million Registered Direct Offering of Common Stock
Intensity Therapeutics, Inc. has announced a $4 million registered direct offering of common stock at $0.80 per share. The offering is expected to close around November 3, 2025, and will help fund clinical trials and general corporate purposes. The company anticipates having sufficient cash runway until the end of Q1 2027.
Read more →INTS▲ +394.6%on this newsshared move
Intensity Therapeutics, Inc. Announces Publication of Clinical Results of INT230-6 for the Treatment of Metastatic or Refractory Cancers in eBioMedicine, a Lancet Discovery Science Journal
Intensity Therapeutics, Inc. announced the publication of its phase 1/2 study results for INT230-6 in treating metastatic or refractory cancers in eBioMedicine. The study demonstrated promising efficacy and a favorable safety profile, with notable immune activation and abscopal effects. A webinar will be held to discuss the findings further.
Read more →INTS▼ -9.6%on this news
Intensity Therapeutics Reports INVINCIBLE-4, Presurgical Triple-Negative Breast Cancer Study Update
Intensity Therapeutics provided an update on the INVINCIBLE-4 trial, reporting a pathological complete response in the first patient of Cohort A. The trial involves administering two doses of INT230-6 followed by standard of care. While safety has been favorable, some patients experienced localized skin irritation, leading to a pause in new patient enrollment for data evaluation.
Read more →INTSIntensity Therapeutics, Inc. to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
Intensity Therapeutics, Inc. will participate in the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025. CEO Lewis H. Bender will engage in a fireside chat discussing the company's innovative cancer therapies, particularly INT230-6, which targets tumors directly and promotes immune system recognition. The conference aims to connect the company with potential investors.
Read more →INTS▲ +8.8%on this news
Intensity Therapeutics, Inc. Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
Intensity Therapeutics, Inc. has announced that it has regained compliance with Nasdaq's minimum stockholders' equity requirement. This follows the company's filing of its quarterly report, which confirmed it has over $2.5 million in stockholders' equity. The CEO expressed optimism about the company's financial outlook, projecting sufficient cash to support operations into 2026.
Read more →INTS▼ -7.6%on this newsshared move
Intensity Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update Over $11 million raised since the beginning of 2Q 2025 Cash runway extended into the second half of 2026 In the INVINCIBL
Intensity Therapeutics has reported its financial results for Q2 2025, raising over $11 million to extend its cash runway into 2026. The INVINCIBLE-4 Study demonstrated promising results with high levels of tumor necrosis in patients receiving INT230-6, while the INVINCIBLE-3 Study has paused new enrollments due to funding challenges. The company aims to resume further studies once sufficient funding is secured. Additionally, they have formed a collaboration to enhance patient awareness regarding upcoming treatment options.
Read more →INTS▲ +11.1%on this news· ran to +23% by day 1shared move
Intensity Therapeutics, Inc. Raises $6.6 Million from At The Market Offering (ATM) Stock Sales in July 2025 Cash runway extended into the second half of 2026 Average sales price per share was over 10% higher than the Jun
Intensity Therapeutics, Inc. has successfully raised $6.6 million through its At-the-Market offering in July 2025, which extends its cash runway into the latter half of 2026. The company reported that the average sale price per share was more than 10% higher than the price from its June 2025 public offering. This capital infusion is aimed at strengthening the company's financial position and supporting the ongoing development of its clinical trials.
Read more →INTSIntensity Therapeutics, Inc. Announces that INT230-6 Achieved 100% Complete Response Rate in Preclinical Models of Malignant Peripheral Nerve Sheath Tumors (MPNST)
Intensity Therapeutics, Inc. announced that its lead investigational drug, INT230-6, achieved a 100% complete response rate in preclinical models of malignant peripheral nerve sheath tumors (MPNST). Conducted at Johns Hopkins University, the study demonstrated that all tested animals responded positively to the treatment. This is a significant milestone, as it showcases the potential of INT230-6 to effectively target a challenging type of cancer. The company is planning further preclinical research with the collaboration of the Staedtke-Bai laboratory.
Read more →INTS▲ +15.1%on this news· ran to -39% by day 3
Intensity Therapeutics, Inc. Announces Proposed Public Offering of Common Stock Shelton, Conn.
Intensity Therapeutics, Inc. has announced its intention to offer shares of common stock in an underwritten public offering, with all shares being sold by the company. The proceeds are aimed at supporting patient enrollment and upcoming data readouts in their clinical studies, particularly for the INVINCIBLE-3 and INVINCIBLE-4 Trials. ThinkEquity will manage the offering, which is subject to SEC regulations and may affect cash flow and operational plans moving forward. This capital raise reflects the company's commitment to its innovative cancer therapies.
Read more →INTS▲ +15.1%on this news· ran to -39% by day 3
Intensity Therapeutics, Inc. Announces Patients Receiving INT230-6 Prior to the Start of Standard-of-Care May Achieve High Levels of Tumor Necrosis in the Ongoing Randomized Controlled Phase 2 INVINCIBLE-4 Study
Intensity Therapeutics, Inc. announced that initial results from its INVINCIBLE-4 study showed patients receiving INT230-6 prior to standard care exhibited high tumor necrosis levels. The ongoing Phase 2 trial focuses on early-stage, operable triple-negative breast cancer patients. The study aims to evaluate the safety and efficacy of INT230-6 in conjunction with standard immunotherapy and chemotherapy. Positive early outcomes suggest INT230-6 could improve patient responses compared to standard treatment alone, potentially enhancing overall survival rates.
Read more →INTS▲ +15.1%on this news· ran to -39% by day 3
Intensity Therapeutics, Inc. Announces Pricing of Public Offering
Intensity Therapeutics, Inc. (INTS) has announced the pricing of a public offering of 6,675,000 shares at $0.30 each, aiming to raise approximately $2 million. The net proceeds will be directed toward patient enrollment and operational costs related to ongoing clinical studies. The offering is set to close on June 13, 2025, pending customary conditions. ThinkEquity is the sole book-running manager for this offering, which includes an option for underwriters to purchase additional shares.
Read more →INTS▲ +24%on this news· ran to +63% by day 3
Intensity Therapeutics, Inc.
Intensity Therapeutics, Inc. has announced its upcoming presentation of the Phase 3 INVINCIBLE-3 clinical trial of INT230-6 at the ASCO 2025 Annual Meeting. This trial aims to evaluate the efficacy and safety of the investigational intratumoral therapy for metastatic soft tissue sarcomas compared to standard systemic chemotherapy. Preliminary results from earlier studies have shown significant tumor necrosis and immune engagement. However, the company has paused new enrollment for the Phase 3 study until sufficient funding is obtained.
Read more →INTSIntensity Therapeutics, Inc. to Collaborate with Author, Model, Executive Producer, Speaker and Breast Cancer Survivor Christine Handy to Raise Patient Awareness of Early-Stage Breast Cancer Treatment Options on the Horizon
Intensity Therapeutics, Inc. announced a collaboration with breast cancer survivor Christine Handy to raise awareness about early-stage breast cancer treatment options. The partnership aims to educate patients on promising new therapies, including Intensity's investigational drug INT230-6. Handy's journey and advocacy work are highlighted as key components of the initiative. Additionally, the company is set to present at the upcoming ASCO Annual Meeting, showcasing its research and ongoing trials in breast cancer and sarcoma.
Read more →INTSIntensity Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Eight Swiss sites are activated in the INVINCIBLE-4 Study, and several patients have been treated European Medicines Agenc
Intensity Therapeutics has reported its financial results for the first quarter of 2025 alongside a corporate update detailing progress in several clinical trials. The INVINCIBLE-4 Study has commenced with eight Swiss sites activated and has received European Medicines Agency authorization for its initiation in France. Despite promising advancements and patient treatment in ongoing studies, the company has faced funding constraints that have compelled it to pause patient enrollment in its Phase 3 sarcoma study until additional funding becomes available. The financial results reflect a net loss reduction compared to the same period last year.
Read more →INTSIntensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Receive European Medicines Agency Authorization to Initiate Phase 2 INVINCIBLE-4 (SAKK/66/22) Study for INT230-6 in the Treatment of Presurgical Triple-Negative Breast Cancer in France
Intensity Therapeutics, Inc. has received authorization from the European Medicines Agency to initiate a Phase 2 study, named INVINCIBLE-4, for its investigational product INT230-6 in treating presurgical triple-negative breast cancer in France. The study, which is also being conducted in Switzerland, aims to evaluate the safety and efficacy of INT230-6 in combination with standard neoadjuvant immunochemotherapy. Preliminary MRI results are promising, showing significant tumor necrosis after initial INT230-6 doses. If successful, this could mark a significant advance in breast cancer treatment.
Read more →INTS▼ -37.1%on this news
Intensity Therapeutics, Inc. Announces $2.35 Million Public Offering
Intensity Therapeutics, Inc. announced a public offering of $2.35 million, involving 3,133,333 shares and associated Series B-1 and B-2 warrants. The net proceeds are intended to facilitate patient enrollment in the INVINCIBLE-4 Study and support ongoing processes for patients in the INVINCIBLE-3 Study, along with general corporate purposes. The offering is scheduled to close on or about April 28, 2025, pending customary conditions. This strategy underscores the company's focus on developing its immune-based cancer therapies.
Read more →INTS▼ -31.9%on this news· ran to -67% by day 3shared move
This presentation contains forward looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties, including statements regarding the develo
Intensity Therapeutics, Inc. has outlined its forward-looking statements regarding its lead product candidate, INT230-6, and the development pathways ahead. The company is focused on a novel cancer treatment approach and has completed two clinical trials with over 200 enrolled patients, although further studies are dependent on securing additional funding. The company highlights both the therapeutic potential of its technology and the rigorous regulatory landscape it faces. Risks associated with the funding and regulatory status of its product candidates are also emphasized, as well as the challenges posed by existing treatment methodologies.
Read more →INTSIntensity Therapeutics Reports 2024 Year End Financial Results and Provides Corporate Update 32 sites are currently contracted in the INVINCIBLE-3 Study, and 25 patients have been screened Eight Swiss sites are activated
Intensity Therapeutics has reported its year-end financial results for 2024, highlighting progress in its clinical studies INVINCIBLE-3 and INVINCIBLE-4. The company has contracted 32 sites for the INVINCIBLE-3 Study and screened 25 patients, while eight sites in Switzerland have been activated for the INVINCIBLE-4 Study. Despite positive developments, the company experienced a significant net loss and a decrease in cash reserves, raising concerns about its financial health moving forward. The firm continues to operate within multiple regulatory jurisdictions, showcasing the potential for broader impact.
Read more →INTSDrug Monitoring Committee Authorizes Continuation of Intensity Therapeutics
Intensity Therapeutics announced that the Data Monitoring Committee has authorized the continuation of its Phase 3 INVINCIBLE-3 Study, evaluating the safety and efficacy of INT230-6 for treating sarcomas. The study is currently recruiting patients in the U.S., Canada, and Europe and aims to improve treatment outcomes for locally recurrent, inoperable, or metastatic soft tissue sarcoma. INT230-6 utilizes a novel approach involving direct intratumoral injection, showing promise in cancer therapy without inducing immunosuppression.
Read more →INTS▲ +8.5%on this news· ran to +40% by day 3
Intensity Therapeutics Provides Business Update Highlighting Key Achievements with Lead Drug Candidate INT230-6
Intensity Therapeutics has announced a business update highlighting key achievements with its lead drug candidate, INT230-6. The company has received authorization from several global regulatory bodies to conduct Phase 3 trials for metastatic soft tissue sarcoma and Phase 2 trials for operable triple-negative breast cancer. Clinical data presented indicated a median overall survival of 21.3 months in prior studies, pointing to promising efficacy. Additionally, discussions for potential collaborations are underway, aiming to expedite product development and market access.
Read more →INTS▼ -12.1%on this news
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Present Phase 2 Data in Presurgical Breast Cancer from the completed INVINCIBLE-2 Study, and an Overview of the Ongoing Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial, INVINCIBLE-4 (SAKK 66/22), at the 2024 San Antonio Breast Cancer Symposium (SABCS)
Intensity Therapeutics, Inc. and SAKK presented findings from the INVINCIBLE-2 Study and updates on the ongoing INVINCIBLE-4 Study focused on treating triple negative breast cancer (TNBC). The INVINCIBLE-4 Study will evaluate the effectiveness of INT230-6 in conjunction with standard neoadjuvant immunochemotherapy, aiming for better pathological complete response rates. Early data from the INVINCIBLE-2 Study indicates significant tumor killing and immune system activation without increasing toxicity, highlighting potential advancements in breast cancer treatment protocols.
Read more →INTS▼ -8.5%on this news
Intensity Therapeutics, Inc. Announces Pricing of $3 Million Registered Direct Offering and Concurrent Private Placement
Intensity Therapeutics, Inc. has announced a $3 million registered direct offering accompanied by a concurrent private placement. The company will sell 1,237,113 shares of common stock at $2.425 each, along with warrants to purchase additional shares. The proceeds are intended for general working capital. The closing of the offerings is anticipated on or around November 22, 2024, pending customary closing conditions.
Read more →INTSIntensity Therapeutics Presents INT230-6 Phase 1/2 Data in Sarcoma and an Overview of its Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society Meeting (CTOS)
Intensity Therapeutics recently presented data from its Phase 1/2 clinical trial of INT230-6, highlighting a median overall survival of 21.3 months for patients with sarcomas. The treatment showcased a favorable safety profile and significant improvements in T-cell activation. The ongoing INVINCIBLE-3 Study aims to further evaluate the efficacy of INT230-6 against standard-of-care therapies in a larger cohort of 333 patients. This research could shift treatment paradigms for patients with these difficult-to-treat sarcomas.
Read more →INTS▼ -8.6%on this newsshared move
Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer Shelton, Conn.
Intensity Therapeutics reported its third quarter 2024 financial results along with a corporate update highlighting the successful dosing of the first patient in a randomized Phase 2 study for presurgical triple-negative breast cancer (TNBC). The company has achieved regulatory authorizations in multiple countries for its INVINCIBLE-3 and INVINCIBLE-4 studies, which focus on therapeutic options for soft tissue sarcoma and TNBC. Despite a net loss of $3.5 million this quarter, Intensity remains committed to exploring their investigational product INT230-6 and its potential impact on cancer treatment.
Read more →INTSIntensity Therapeutics Selected for Oral Podium Presentation in a Late-Breaking Session at the 2024 Annual Connective Tissue Oncology Society (Sarcomas) Meeting
Intensity Therapeutics, Inc. announced that its Phase 3 trial will be presented orally at the 2024 Connective Tissue Oncology Society meeting in San Diego. Dr. Christian F. Meyer will discuss the company's innovative cancer therapy, INT230-6, and its Phase 2 results along with the INVINCIBLE-3 trial design. This presentation highlights the progress Intensity has made in the field of cancer therapeutics, especially for soft tissue sarcomas, amidst a growing interest in immune-based treatments.
Read more →INTS▲ +6.6%on this news
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Announce the First Patient Dosed in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 / SAKK 66/22)
Intensity Therapeutics, Inc. and the Swiss Group for Clinical Cancer Research SAKK have announced the dosing of the first patient in the INVINCIBLE-4 Phase 2 clinical trial. This study will evaluate the efficacy of Intensity's lead candidate INT230-6, combined with standard-of-care treatment versus standard-of-care alone for patients with localized triple-negative breast cancer. The trial aims to assess the impact of INT230-6 on pathological complete response rates, with hopes of improving patient outcomes in this aggressive cancer subtype. The collaboration underscores a significant step in the development of innovative cancer therapies.
Read more →INTSIntensity Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Intensity Therapeutics, Inc. is set to present at the H.C. Wainwright 26th Annual Global Investment Conference on September 11, 2024. CEO Lewis H. Bender will deliver a corporate overview, highlighting the company's novel immune-based intratumoral cancer therapies and ongoing clinical trials. The company has completed enrollment for multiple studies and aims to demonstrate the potential for its INT230-6 treatment to turn aggressive cancers into chronic diseases. A live webcast of the presentation will be available, along with opportunities for one-on-one meetings at the conference.
Read more →INTSIntensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma Collaboration agreement with Th
Intensity Therapeutics has reported its financial results for the second quarter of 2024, including the dosing of the first patient in its Phase 3 study for soft tissue sarcoma. The company has also secured a collaboration with SAKK for a Phase 2 study in early-stage breast cancer. Despite a net loss increase and rising expenses in R&D, Intensity's cash reserves are expected to sustain operations into early 2025. The advancements in their trial programs mark significant steps forward for the company and its lead drug candidate INT230-6.
Read more →INTSIntensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma
Intensity Therapeutics, Inc. has initiated its global Phase 3 study of INT230-6, marking the first patient being dosed for treating metastatic soft tissue sarcoma. This trial aims to compare INT230-6, an investigational product, against established systemic chemotherapy for patients with advanced STS. A total of approximately 333 patients are expected to be enrolled, with the primary objective being overall survival. The initiation follows encouraging results from earlier trials indicating improved survival outcomes in patients with metastatic disease.
Read more →INTS▲ +9.3%on this news
Intensity Therapeutics, Inc. Announces the Appointment of Thomas Dubin to Its Board of Directors Shelton, CT
Intensity Therapeutics, Inc. announced the appointment of Thomas Dubin to its Board of Directors, effective May 14, 2024. Dubin brings significant experience from his previous role at Alexion Pharmaceuticals, which could be beneficial as the company prepares to enter Phase 3 clinical trials for its lead product candidate, INT230-6. The Board has been expanded from four to five members, with four being independent directors. Dubin's role may strengthen the company's business development and regulatory pathways as they advance their novel cancer treatment strategies.
Read more →INTS▲ +6.4%on this news· ran to +28% by day 3shared move
Intensity Therapeutics, Inc. and The Swiss Group for Clinical Cancer Research SAKK Sign a Collaboration Agreement to Conduct a Phase 2 Randomized, Clinical Trial in Early-Stage Breast Cancer in Europe for INT230-6, Intensity
Intensity Therapeutics, Inc. has partnered with The Swiss Group for Clinical Cancer Research SAKK to conduct a Phase 2 randomized trial for its investigational drug INT230-6 in early-stage triple-negative breast cancer. The trial, known as the INVINCIBLE-4 Study, will evaluate the effects of INT230-6 combined with standard care versus standard care alone. Results from prior studies suggest INT230-6 can significantly necrotize large tumors. Patient enrollment will occur in Switzerland and selected European countries, with efficacy data expected in late 2025.
Read more →INTSIntensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast ca
Intensity Therapeutics reported its first quarter 2024 financial results, highlighting progress in clinical development for its lead candidate INT230-6. The company plans to initiate two significant clinical trials: the INVINCIBLE-3 Study for sarcoma and the INVINCIBLE-4 Study for triple negative breast cancer, both expected to start mid-2024. Despite a notable rise in research and development expenses, the company reported sufficient cash reserves to continue operations until early 2025. Contracts for trial sites are in progress, reflecting ongoing interest in the studies.
Read more →INTS▼ -7.8%on this news
Intensity Therapeutics to Participate in the LD Micro Invitational XIV Conference April 8 - 9, 2024
Intensity Therapeutics will present a corporate overview at the LD Micro Invitational XIV Conference on April 9, 2024. CEO Lewis H. Bender will discuss the company's innovative immune-based intratumoral cancer therapies, specifically its drug INT230-6. The therapy aims to improve patient outcomes in various cancers, including breast cancer and soft tissue sarcoma, with ongoing Phase 1/2 and Phase 3 clinical trials. Investors will have the opportunity for one-on-one meetings during the conference to discuss future developments.
Read more →INTSIntensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancer Year-end ca
Intensity Therapeutics has reported its full-year 2023 financial results, highlighting advancements for INT230-6 into late-stage clinical programs targeting soft tissue sarcoma and breast cancer. The company received FDA approval to proceed with a Phase 3 study for INT230-6, which has shown promising efficacy and safety in prior trials. 2023 also saw the completion of a Phase 1/2 study and successful presentations at major oncology conferences. Despite a reported increase in net losses and operational expenses, the company maintains a robust cash position expected to fund itself through Q1 2025.
Read more →INTSIntensity Therapeutics to Participate in the 36th Annual Roth Conference March 17 to 19, 2024
Intensity Therapeutics, Inc. announced the participation of CEO Lewis H. Bender at the 36th Annual Roth Conference on March 19, 2024. The company focuses on developing immune-based intratumoral cancer therapies, notably INT230-6, which aims to turn 'cold' tumors 'hot.' This event may provide insights into the company's future plans and ongoing clinical trials, including a Phase 3 trial in soft tissue sarcoma and a Phase 2/3 program in triple negative breast cancer. A live webcast of the presentation will be available for interested parties.
Read more →INTSIntensity Therapeutics to Present at the 2024 BIO CEO & Investor Conference
Intensity Therapeutics, a biotechnology company focused on cancer therapies, announced that its CEO, Lewis H. Bender, will present at the 2024 BIO CEO & Investor Conference in New York on February 26, 2024. The firm continues to progress with its lead therapy, INT230-6, which is in late-stage clinical trials. This therapy aims to enhance immune recognition and treatment effectiveness against tumors. The company is also preparing to enter new clinical phases for other cancer treatments.
Read more →INTS▼ -7.8%on this news· ran to -18% by day 3
Intensity Therapeutics Provides Business Update Reflecting Progress in Phase 3 Sarcoma Program
Intensity Therapeutics announced a business update regarding its Phase 3 clinical trial for INT230-6 in soft tissue sarcoma. The FDA gave a 'Study May Proceed' letter, enabling the company to start this trial in the first half of 2024. The trial will explore INT230-6 as a monotherapy compared to standard care. Preliminary data show a significant improvement in survival and a favorable safety profile for INT230-6, marking a potential advancement in sarcoma treatment.
Read more →INTSIntensity Therapeutics Appoints Joseph Talamo, CPA, as Chief Financial Officer Mr. Talamo brings over 25 years of experience leading financial strategies to support both publicly traded and privately held, development an
Intensity Therapeutics has appointed Joseph Talamo, CPA, as its Chief Financial Officer. Talamo, who has over 25 years of experience in financial strategies for biopharmaceutical companies, previously held CFO positions at HiberCell and Caladrius Biosciences. His role will include developing financial strategies and leading investor relations as the company prepares for late-stage clinical trials of its lead asset, INT230-6, which aims to improve cancer treatment outcomes.
Read more →INTS▲ +72%on this news· ran to +147% by day 3shared move
Intensity Therapeutics Presents Positive INT230-6 Data in Patients with Early-Stage Breast Cancer in a Podium Poster Spotlight Discussion at the 2023 SABCS
Intensity Therapeutics presented positive data on its drug INT230-6 at the 2023 SABCS, demonstrating significant tumor necrosis and immune activation in patients with early-stage breast cancer. The Phase 2 INVINCIBLE trial showed that INT230-6 can induce over 95% tumor necrosis and enhance T-cell diversity, maintaining a favorable safety profile. The trial's findings support INT230-6's potential as a presurgical treatment, addressing a critical unmet need in breast cancer therapy. Patient interest in this novel approach was notably high, indicating strong demand for innovative cancer treatments.
Read more →INTS▲ +28.5%on this news· ran to +42% by day 3
Intensity Therapeutics Selected for Spotlight Oral Presentation at the 2023 San Antonio Breast Cancer Symposium
Intensity Therapeutics, Inc. has been chosen for a spotlight oral presentation at the upcoming 2023 San Antonio Breast Cancer Symposium, scheduled for December 8, 2023. Dr. Angel Arnaout will present findings on the efficacy and immunomodulatory effects of INT230-6 in early-stage breast cancer. The presentation will focus on the results from the INVINCIBLE trial, emphasizing the potential of their immune-based cancer therapies. This recognition underscores Intensity's innovative approach in the field of oncology.
Read more →INTSIntensity Therapeutics Reports Third Quarter Financial Results and Provides Corporate Update Presented positive Phase 1/2 clinical data for INT230-6 in patients with refractory soft tissue sarcoma at Connective Tissue On
Intensity Therapeutics reported strong third quarter financial results, highlighting positive Phase 1/2 clinical data for INT230-6 in treating refractory soft tissue sarcoma, with a notable 93% disease control rate. The company received Orphan Drug Designation for INT230-6 and reported successful financial maneuvers including an upsized IPO, securing $20.2 million in net proceeds. Intensity remains focused on advancing its clinical studies, planning to file an IND for a Phase 3 study of INT230-6 by the end of 2023 while managing increasing research and administrative costs.
Read more →INTSIntensity Therapeutics Presents Positive INT230-6 Data in Patients with Refractory Soft Tissue Sarcoma at the Connective Tissue Oncology Society Annual Meeting 2023
Intensity Therapeutics has presented positive data for INT230-6, a novel therapy designed for patients with refractory soft tissue sarcoma, at the Connective Tissue Oncology Society Annual Meeting 2023. The therapy achieved a 93% disease control rate and extended patient survival by nearly 15 months compared to a synthetic control group. Importantly, INT230-6 was reported to have a favorable safety profile, with most adverse events being mild. The company is now preparing for a Phase 3 study of INT230-6 as a monotherapy.
Read more →INTSIntensity Therapeutics to Present at the H.C. Wainwright 25 th Annual Global Investment Conference
Intensity Therapeutics, Inc. announced that its President and CEO, Lewis H. Bender, will present a company overview at the H.C. Wainwright 25th Annual Global Investment Conference on September 11. The presentation will cover the company's innovative immune-based intratumoral cancer therapies and its lead product candidate, INT230-6, which targets solid tumors. The company is currently engaging in multiple clinical collaborations with major pharmaceutical entities to advance its research and development efforts. Attendees can participate in in-person and virtual one-on-one meetings during the event.
Read more →INTSIntensity Therapeutics Reports Second Quarter Financial Results and Provides Corporate Update Closed Upsized IPO Priced at Top-Of-Range, Full Exercise of the Over-Allotment Nets $20.4 Million in Proceeds Data Presented a
Intensity Therapeutics reported positive financial results for the second quarter of 2023 and an upsized IPO that raised $20.4 million. The recent data presented at ASCO highlighted the effectiveness of its lead asset, INT230-6, in prolonging survival rates for patients with relapsed and refractory metastatic sarcomas. The company's CEO emphasized the growing interest from physicians and plans for further trials, including a phase 3 study in soft tissue sarcomas. With sufficient cash to fund operations until 2025, the company is poised for significant clinical advancements.
Read more →INTSIntensity Therapeutics, Inc. Announces the Closing and Full Exercise of the Over-Allotment Option from its Upsized Initial Public Offering, Raising a Total of $22.425 Million in Gross Proceeds
Intensity Therapeutics, Inc. has successfully closed its initial public offering, raising $22.425 million in gross proceeds, included in which is the full exercise of the underwriters' over-allotment option. The funds will support the company's development of proprietary immune-based cancer therapies. The ICO was managed by The Benchmark Company and Freedom Capital Markets and is set to advance the company's innovative treatment strategies for solid tumors like sarcoma and breast cancer. Intensity's ongoing collaborations with major pharmaceutical companies further underscore its potential in the biotechnology sector.
Read more →INTSIntensity Therapeutics, Inc. Announces Pricing of Upsized Initial Public Offering, Raising Approximately $19.5 Million in Gross Proceeds
Intensity Therapeutics, Inc. has announced the successful pricing of its upsized initial public offering, raising approximately $19.5 million in gross proceeds. The offering consists of 3,900,000 shares priced at $5.00 each, with an option for underwriters to purchase additional shares. Trading is set to commence on the Nasdaq Capital Market under the ticker symbol 'INTS'. The offering is expected to close on July 5, 2023, contingent on customary closing conditions. Funds from the offering will be used to further develop the company's immune-based cancer therapies.
Read more →Competitive Position
How INTS ranks across every disease it competes inCompetitive Position is a premium feature
See how INTS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial